Novavax Valuation
| NVAX Stock | USD 4.19 0.12 2.95% |
At this time, the firm appears to be undervalued. Novavax secures a last-minute Real Value of $8.2 per share. The latest price of the firm is $4.19. Our model forecasts the value of Novavax from analyzing the firm fundamentals such as Profit Margin of (0.55) %, current valuation of 281.74 M, and Return On Equity of -8.98 as well as examining its technical indicators and probability of bankruptcy. In general, most investors recommend acquiring undervalued stocks and dropping overvalued stocks since, at some point, asset prices and their ongoing real values will merge together. Key fundamental drivers impacting Novavax's valuation include:
Price Book 49.522 | Enterprise Value 281.7 M | Enterprise Value Ebitda (0.53) | Price Sales 0.6089 | Forward PE 1.7816 |
Undervalued
Today
Please note that Novavax's price fluctuation is moderately volatile at this time. Calculation of the real value of Novavax is based on 3 months time horizon. Increasing Novavax's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Novavax is useful when determining the fair value of the Novavax stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Novavax. Since Novavax is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Novavax Stock. However, Novavax's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.19 | Real 8.2 | Target 20.6 | Hype 4.18 |
The real value of Novavax Stock, also known as its intrinsic value, is the underlying worth of Novavax Company, which is reflected in its stock price. It is based on Novavax's financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Novavax's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Novavax's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Novavax helps investors to forecast how Novavax stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Novavax more accurately as focusing exclusively on Novavax's fundamentals will not take into account other important factors: Traditionally analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Novavax's intrinsic value based on its ongoing forecasts of Novavax's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Novavax's closest peers. When choosing an evaluation method for Novavax, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using both methods to arrive at a better estimate.
Novavax Investments |
|
Novavax Valuation Trend
Knowing Novavax's actual value is paramount for traders to make sound investment determinations. Novavax's real value is not only important for the investor to make better decisions but also for a more accurate overall view of Novavax's financial worth over time since having this information enables investors and analysts to forecast the earnings more efficiently. Using both Novavax's enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing descisions.
Novavax Market Cap
Novavax is regarded fourth in market capitalization category among related companies. Market capitalization of Health Care industry is now estimated at about 279.6 Billion. Novavax adds roughly 569.61 Million in market capitalization claiming only tiny portion of equities under Health Care industry.Novavax Valuation Ratios as Compared to Competition
Comparative valuation techniques use various fundamental indicators to help in determining Novavax's current stock value. Our valuation model uses many indicators to compare Novavax value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Novavax competition to find correlations between indicators driving Novavax's intrinsic value. More Info.Novavax is regarded fourth in price to earning category among related companies. It is considered to be number one stock in price to book category among related companies . Price To Book Ratio is likely to rise to -0.64 in 2024. Comparative valuation analysis is a catch-all model that can be used if you cannot value Novavax by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Novavax's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Novavax's earnings, one of the primary drivers of an investment's value.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Novavax's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Novavax and how it compares across the competition.
About Novavax Valuation
The stock valuation mechanism determines the current worth of Novavax on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Novavax. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Novavax based exclusively on its fundamental and basic technical indicators. By analyzing Novavax's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Novavax's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Novavax. We calculate exposure to Novavax's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Novavax's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 704.2 M | 739.4 M | |
| Pretax Profit Margin | (0.55) | (0.58) | |
| Operating Profit Margin | (0.42) | (0.44) | |
| Net Loss | (0.55) | (0.58) | |
| Gross Profit Margin | 0.72 | 0.75 |
8 Steps to conduct Novavax's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Novavax's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Novavax's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Novavax's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Novavax's revenue streams: Identify Novavax's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Novavax's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Novavax's growth potential: Evaluate Novavax's management, business model, and growth potential.
- Determine Novavax's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Novavax's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Novavax Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Novavax does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 100.8 M | |
| Forward Price Earnings | 1.7816 |
Novavax Current Valuation Indicators
Valuation refers to the process of determining the present value of Novavax and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Novavax we look at many different elements of the entity such as Novavax's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation. Novavax's valuation analysis is also a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Novavax's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Novavax, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Novavax's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Novavax's worth.When determining whether Novavax offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novavax's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novavax Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novavax Stock: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.Note that the Novavax information on this page should be used as a complementary analysis to other Novavax's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Complementary Tools for Novavax Stock analysis
When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |
Is Novavax's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novavax. If investors know Novavax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novavax listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.41) | Revenue Per Share 9.762 | Quarterly Revenue Growth (0.18) | Return On Assets (0.17) | Return On Equity (8.98) |
The market value of Novavax is measured differently than its book value, which is the value of Novavax that is recorded on the company's balance sheet. Investors also form their own opinion of Novavax's value that differs from its market value or its book value, called intrinsic value, which is Novavax's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novavax's market value can be influenced by many factors that don't directly affect Novavax's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novavax's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novavax is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novavax's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.